

IMAGE

Check for updates


Infographic: Everest II study “Which is superior? Combination therapy or monotherapy for polypoidal choroidal vasculopathy (PCV) treatment”

Chinmayi Himanshuroy Vyas¹, Pooi Wah Lott¹, Rubamalar Gunatheesan¹, Shaun Sebastian Sim^{1,2}, Christopher Ziyu Sun¹, Kelvin Yi Chong Teo^{1,2} and Chui Ming Gemmy Cheung^{1,2}

© The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021

Eye (2022) 36:1140–1141; <https://doi.org/10.1038/s41433-021-01873-8>

PCV polypoidal choroidal vasculopathy, IVR intravitreal ranibizumab, vPDT verteporfin photodynamic therapy, ETDRS early treatment diabetic retinopathy study, ICG indocyanine green angiography [1, 2].



¹Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore 168751, Singapore. ²Duke-NUS Medical School, National University of Singapore, Singapore, Singapore. ✉email: gemmy.cheung.c.m@singhealth.com.sg

Received: 10 November 2021 Revised: 21 November 2021 Accepted: 23 November 2021
Published online: 9 January 2022

REFERENCES

1. Koh A, Lai TYY, Takahashi K, Wong TY, Chen L-J, Ruamviboonsuk P, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. *JAMA Ophthalmol.* 2017;135:1206–13.
2. Lim TH, Lai TYY, Takahashi K, Wong TY, Chen L-J, Ruamviboonsuk P, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II Randomized Clinical Trial. *JAMA Ophthalmol.* 2020;138:935–42.

AUTHOR CONTRIBUTIONS

CHV, LPW, KYCT, and CMGC developed the infographic design. CHV prepared the infographic. CMGC, SSS, KYCT, LPW, CZS, and RG edited and reviewed the infographic and provided the scientific expert advice.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Chui Ming Gemmy Cheung.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.